From: businesswire.com Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases The unique tumor insights CELsignia generates enable identification of new potential applications for targeted therapies and development of potential first-in-class drugs Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing an …
Lawrence + Memorial Hospital Using Precision Medicine to Treat Breast Cancer
Submitted by: Emily Montemerlo From: medicine.yale.edu Yale New Haven Health is bringing precision medicine to breast cancer patients at Lawrence + Memorial Hospital (L+M) with a new imaging agent that is designed specifically to detect certain types of recurrent or metastatic breast cancer. Last year for the first time, the Food and Drug Administration (FDA) approved a Positron Emission Tomography …
New UT research predicts effectiveness of breast cancer treatments — here’s how
By: Kelsey Thompson From: ketk.com Dr. Thomas Yankeelov of the University of Texas at Austin might specialize in cancer research, but it was a deep dive into a meteorology book a decade ago that helped inspire new research into detecting the effectiveness of breast cancer treatments in patients. Before math and physics factored into meteorology research, the field was reliant …
Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer
From: precisiononcologynews.com Veru, a Miami-based cancer drugmaker, on Wednesday said it has begun enrolling previously treated hormone receptor (HR)-positive, HER2-negative metastatic breast cancer patients in a Phase III trial of its anti-androgen receptor therapy enobosarm. The registration-directed trial, dubbed ARTEST, is specifically exploring the activity of enobosarm in advanced breast cancer patients with androgen receptor (AR)-positive and estrogen receptor (ER)-positive …
First CDK4/6 inhibitor OK’d for Early, High-Risk Breast Cancer
By: Mike Bassett From: medpagetoday.com Abemaciclib approved with endocrine therapy for hormone receptor-positive/HER2-negative disease The FDA approved the CDK4/6 inhibitor abemaciclib (Verzenio), in combination with standard adjuvant endocrine therapy, for certain patients with early breast cancer who are at high risk of recurrence, Eli Lilly announced. Indicated for patients who are node-positive and have hormone receptor-positive/HER2-negative disease, eligibility for the …
More Data Needed on Tissue-Agnostic Therapy Use in Breast Cancer
By: Emily Brill From: ajmc.com A new report suggests that much remains to be seen about tissue-agnostic therapies’ effectiveness for treating breast cancer, as “a paucity of data” exists regarding this relatively new treatment’s impact on the disease, and that additional studies are needed to evaluate how well these therapies work on treating metastatic breast cancer (mBC). The investigators reviewed …
Clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain
By: Focused Ultrasound Foundation From: medicalxpress.com In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain. In this Phase I clinical trial for Her2-positive breast cancer patients, the Sunnybrook team captured …
USC Opens Phase II Trial of Ambrx’s ARX788 for HER2-Positive Breast Cancer
From: precisiononcologynews.com The University of Southern California’s Norris Comprehensive Cancer Center on Monday said it has opened a Phase II trial of Ambrx’s antibody-drug conjugate ARX788 for advanced HER2-positive breast cancer patients. The trial, which is sponsored by La Jolla, California-based Ambrx, will involve roughly 200 HER2-positive metastatic breast cancer patients who have previously received trastuzumab emtansine (Genentech’s Kadcyla; T-DM1), …
Researchers Discover New Molecule That Eliminates Breast Cancer
By: Ty & Charlene Bollinger From: thetruthaboutcancer.com Each year, over 250,000 women (and nearly 2500 men) are diagnosed with breast cancer in the United States. 1 in 8 women will be diagnosed with invasive breast cancer in their lifetime. Approximately three-quarters of cases are a type called estrogen receptor-positive, in which the cancer cells have a receptor in their membranes …
Investigators Combine Zanidatamab With Evorpacept to Potentially Improve Outcomes in HER2-Expressing Breast Cancer
By: Nichole Tucker From: targetedonc.com Zanidatamab in combination with evorpacept has been dosed for the first time in a patient with HER2-low breast cancer. The first patient has been dosed with the combination of zanidatamab and evorpacept (ALX148) in a phase 1b/2 study evaluating the safety and efficacy of the combination in HER2-low breast cancer, and additional non-breast HER2-expressing solid …